Longbow Starts PetMed Express (PETS) at Buy
More News related to PETS
- PetMed Express (PETS) Tops Q4 Earnings Views
- PetMed Express, Inc. D/B/A 1-800-PetMeds Announces Record Financial Results for Fiscal 2009
- PetMed Express (PETS) Tops Q3 Earnings Views
- Trading Radar for 1/20: IBM (IBM), J&J (JNJ), CSX (CSX), State Street (STT), Suncor (SU), TD Ameritrade (AMTD) Report
- CL King Starts PetMed Express (PETS) at Strong Buy
Longbow Research initiates coverage on PetMed Express (Nasdaq: PETS) with a Buy rating.
PetMed Express, Inc., doing business as 1-800-PetMeds, engages in the marketing and sale of prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. Its prescription medications include heartworm preventatives, thyroid and arthritis medications, antibiotics, and other specialty medications, as well as generic substitutes.
Related Categories
New CoverageStocks Mentioned
-0.48Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
